Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
Brink, Mirian; Meeuwes, Frederik O.; van der Poel, Marjolein W.M.; Kersten, Marie José; Wondergem, Mariëlle; Mutsaers, Pim G.N.J.; Böhmer, Lara H.; Woei-A-Jin, F. J.Sherida H.; Visser, Otto; Oostvogels, Rimke; Jansen, Patty M.; Plattel, Wouter; Huls, Gerwin A.; Vermaat, Joost S.P.; Nijland, Marcel
(2022) Blood, volume 140, issue 9, pp. 1009 - 1019
(Article)
Abstract
Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of etoposide (CHOEP) and consolidation with autologous stem cell transplantation (ASCT) are preferred in some countries, randomized trials are lacking. This nationwide population-based study assessed the impact of etoposide
... read more
and ASCT on overall survival (OS) among patients aged 18 to 64 years with stage II to IV anaplastic large-cell lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), or PTCL not otherwise specified (NOS) diagnosed between 1989 and 2018 using the Netherlands Cancer Registry. Patients were categorized into 2 calendar periods, representing pre- and post-eras of etoposide and ASCT, respectively. A total of 1427 patients were identified (ALCL, 35%; AITL, 21%; and PTCL NOS, 44%). OS increased from 39% in the period from 1989 to 2009 to 49% in the period of 2009 to 2018 (P < .01). Five-year OS was superior for patients treated with CHOEP vs CHOP (64% and 44%, respectively; P < .01). When adjusted for subtype, International Prognostic Index score, and ASCT, the risk of mortality was similar between the 2 groups, except for patients with ALK+ ALCL, for whom the risk of mortality was 6.3 times higher when treated with CHOP vs CHOEP. Patients undergoing consolidation with ASCT had superior 5-year OS of 81% compared with 39% for patients not undergoing ASCT (P < .01), regardless of whether complete remission was achieved. In patients aged <65 years with advanced-stage ALK- ALCL, AITL, or PTCL, the use of ASCT consolidation, but not the addition of etoposide, was associated with improved OS.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cohort Studies, Cyclophosphamide/therapeutic use, Doxorubicin/therapeutic use, Etoposide/therapeutic use, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Large-Cell, Anaplastic, Lymphoma, T-Cell, Peripheral/pathology, Male, Middle Aged, Prednisone/therapeutic use, Receptor Protein-Tyrosine Kinases, Testicular Neoplasms, Transplantation, Autologous, Vincristine/therapeutic use, Hematology, Biochemistry, Cell Biology, Immunology, Journal Article
ISSN: 0006-4971
Publisher: American Society of Hematology
Note: Funding Information: The authors thank the registrars of the Netherlands Cancer Registry (NCR) for their dedicated data collection. The nationwide population-based NCR is maintained and hosted by the Netherlands Comprehensive Cancer Organisation. Publisher Copyright: © 2022 American Society of Hematology © 2022 by The American Society of Hematology.
(Peer reviewed)